J&J and Bayer's Xarel to cuts recurrence of dangerous blood clots in study

WASHINGTON (Reuters) - Longer-term use of the oral blood thinner Xarelto significantly cut the risk of recurrence of potentially life-threatening blood clots with no additional major bleeding compared with low-dose aspirin in patients at elevated risk, according to data presented on Saturday.